Mirum Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MIRM and other ETFs, options, and stocks.

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. 

CEO
Christopher Peetz
CEOChristopher Peetz
Employees
372
Employees372
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
2018
Founded2018
Employees
372
Employees372

MIRM Key Statistics

Market cap
6.53B
Market cap6.53B
Price-Earnings ratio
-7.88
Price-Earnings ratio-7.88
Dividend yield
Dividend yield
Average volume
1.10M
Average volume1.10M
High today
$109.60
High today$109.60
Low today
$102.93
Low today$102.93
Open price
$103.93
Open price$103.93
Volume
1.77M
Volume1.77M
52 Week high
$112.00
52 Week high$112.00
52 Week low
$42.89
52 Week low$42.89

Stock Snapshot

Mirum Pharmaceuticals(MIRM) stock is priced at $107.16, giving the company a market capitalization of 6.53B. It carries a P/E multiple of -7.88.

As of 2026-05-10, Mirum Pharmaceuticals(MIRM) stock has fluctuated between $102.93 and $109.60. The current price stands at $107.16, placing the stock +4.1% above today's low and -2.2% off the high.

Mirum Pharmaceuticals(MIRM) shares are trading with a volume of 1.77M, against a daily average of 1.1M.

During the past year, Mirum Pharmaceuticals(MIRM) stock moved between $42.89 at its lowest and $112.00 at its peak.

During the past year, Mirum Pharmaceuticals(MIRM) stock moved between $42.89 at its lowest and $112.00 at its peak.

MIRM News

The Motley Fool 3d
Mirum Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, May 6, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Christopher Peetz President — Peter Radovich...

Mirum Q1 2026 Earnings Call Transcript
Simply Wall St 4d
Why Mirum Pharmaceuticals Is Up 12.6% After Positive Phase 2b Volixibat Itch Data in PSC

Mirum Pharmaceuticals recently reported that its Phase 2b VISTAS trial of volixibat in primary sclerosing cholangitis met the primary endpoint, showing a statis...

Why Mirum Pharmaceuticals Is Up 12.6% After Positive Phase 2b Volixibat Itch Data in PSC
Benzinga 6d
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets

PSC is a chronic, progressive, and rare liver disease characterized by inflammation, scarring, and narrowing (strictures) of the bile ducts. Volixibat Shows Sta...

Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

More MIRM News

Nasdaq 6d
Mirum Pharma's Phase 2b Study Of Volixibat For Sclerosing Cholangitis Meets End Point, Shares Gain

(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM), Monday said that its VISTAS Phase 2b study evaluating Volixibat met primary endpoint in patients with primary sc...

Mirum Pharma's Phase 2b Study Of Volixibat For Sclerosing Cholangitis Meets End Point, Shares Gain
TipRanks 6d
Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own MIRM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.